CLS Form 4: Director Francoise Colpron receives 155 director share units

Rhea-AI Filing Summary

Celestica director Francoise Colpron received 155 director share units on 09/30/2025, increasing her direct beneficial ownership to 404 common shares. Each director share unit is a contingent right to one common share or cash equivalent at the issuer's discretion when the holder stops serving as a director or other service provider. The units were granted at no cash price and are recorded as an acquisition on Form 4. The filing was signed by an attorney-in-fact on 10/01/2025. This disclosure reflects a routine equity grant to a non-employee director rather than an open-market purchase.

Insights

Financial Analyst

TL;DR: Routine director equity grant—small share-unit award that modestly increases insider ownership; no cash paid.

The Form 4 shows a non-derivative acquisition of 155 director share units for Francoise Colpron on 09/30/2025, bringing reported direct beneficial ownership to 404 shares. The units carry a contingent right to one common share or cash on termination of service and were recorded at $0 cash price. This is a standard board compensation mechanism and, based solely on the disclosure, has limited immediate financial impact on the company or capital structure.

Corporate Governance Expert

TL;DR: Governance-standard award aligning director pay with shareholder interests; disclosure is complete for this grant.

The filing documents a board compensation award typical for non-employee directors: 155 director share units convertible to shares or cash upon cessation of service. The form identifies the reporting person as a director and records the grant as an acquisition with no purchase price. The explanation clarifies conversion conditions. From a governance perspective, the disclosure is appropriate and transparent regarding the nature and timing of the award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Colpron Francoise

(Last) (First) (Middle)

5140 YONGE STREET

SUITE 1900

(Street)

TORONTO A6 M2N 6L7

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CELESTICA INC [ CLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Share Units	(1)	09/30/2025		A		155		(1)	(1)	Common Shares	155	$0	404	D

Explanation of Responses:

1. Each director share unit represents a contingent right to receive one common share or an equivalent value in cash at the Issuer's discretion when the holder ceases to serve the Issuer as any of a director, consultant or other service provider.

	/s/ Tracy Connelly McGilley, attorney-in-fact	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Celestica (CLS) disclose in this Form 4 filing?

The filing reports that director Francoise Colpron was granted 155 director share units on 09/30/2025, increasing her direct beneficial ownership to 404 common shares.

What are director share units granted to Francoise Colpron?

Each director share unit represents a contingent right to receive one common share or an equivalent cash amount when the holder ceases to serve the issuer as a director or service provider.

Did Francoise Colpron pay cash for the share units?

No. The Form 4 records the grant with a reported $0 price for the director share units.

When was the Form 4 signed and by whom?

The filing was signed by Tracy Connelly McGilley, attorney-in-fact, on 10/01/2025.

Does this Form 4 show any derivative transactions or option exercises?

No. The reported transaction is a non-derivative acquisition of director share units convertible to common shares or cash.